Relating Structure to Function in Optic Neuropathies

视神经病变的结构与功能的关系

基本信息

  • 批准号:
    10547776
  • 负责人:
  • 金额:
    $ 38.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-01-01 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION Glaucoma is a group of diseases that results in a pathological loss of retinal ganglion cells (RGC) and irreversible vision loss. Although glaucoma is an optic neuropathy with characteristic optic nerve head (ONH) changes, risk of developing disease is not based on ONH structure, but factors including intraocular pressure (IOP), central corneal thickness, age, race and family history. In early disease, there is significant thinning of the optic nerve head (ONH) rim tissue that precedes RGC loss. We hypothesize that the early thinning of the ONH neuroretinal rim tissue (NRR) is related to changes in the glia and extracellular matrix, but not axonal content, which we will investigate using immunohistochemistry and 3D serial block-face scanning electron microscopy in the non- human primate experimental glaucoma model. We also hypothesize that the ONH NRR response to transient changes in IOP is a reflection of the NRR tissue composition, and predictive of the rate of RGC loss (SA1). Clinically, RGC content of the eye is assessed with non-invasive imaging using optical coherence tomography (OCT), for structure, and visual thresholds, for function. OCT structural measures have low variability and have revolutionized how glaucoma is assessed. However, the RGC correspondence to OCT measures is not known, and cannot be estimated from in vivo measures. In fact, the linear relationship for all OCT derived RGC measures is not correct. In SA2, the relationship between OCT derived measures of the circumpapillary retinal nerve fiber layer and ganglion cell inner plexiform thickness will be related to RGC content at all stages of neuropathy using rigorous histological methods. The goal of this aim is develop methods to estimate RGC content in the eye. For a disease that results in irreversible vision loss, it is important that visual function is also assessed accurately. In principal there should also be excellent correspondence between RGC content estimates from OCT measures and that from visual thresholds. Because structural measures are objective and less variable, it would be ideal to accurately predict vision using structural measures. However there is significant discrepancy between structural and functional measures. Some of the reasons for this disjunction is that visual function tests do not use appropriate spatial sampling and stimulus size. In these experiments we will investigate the relationship between RGC content and visual thresholds using higher spatial density and varying stimulus sizes (SA3). Our goal is to establish robust methods to predict visual function based on non-invasive structural imaging. Overall, these studies are designed to improve our understanding of disease pathophysiology and the ability to accurately monitor it in clinical practice.
描述 青光眼是一组导致视网膜神经节细胞(RGC)的病理性损失和不可逆的视网膜病变的疾病。 视力丧失虽然青光眼是一种具有特征性视神经乳头(ONH)变化的视神经病变,但风险 发展中疾病的发病率不是基于ONH结构,而是包括眼内压(IOP)、中枢神经系统疾病(CNS)、 角膜厚度、年龄、种族和家族史。在疾病早期,视神经明显变薄 头(ONH)边缘组织之前RGC损失。我们假设ONH神经视网膜的早期变薄 边缘组织(NRR)与胶质细胞和细胞外基质的变化有关,但与轴突含量无关,我们将 使用免疫组织化学和3D连续块面扫描电子显微镜研究非 人灵长类实验性青光眼模型。我们还假设ONH NRR对短暂的 IOP的变化是NRR组织组成的反映,并且是RGC损失率的预测(SA1)。 临床上,使用光学相干断层扫描的非侵入性成像评估眼睛的RGC含量 (OCT)结构的阈值,功能的阈值。OCT结构测量具有低可变性, 彻底改变了青光眼的评估方法。然而,RGC与OCT测量的对应关系尚不清楚, 并且不能从体内测量中估计。事实上,所有OCT导出的RGC测量的线性关系 是不正确的。在SA2中,视乳头周围视网膜神经纤维的OCT衍生测量之间的关系 层和神经节细胞内丛状厚度将与RGC含量在所有阶段的神经病变,使用 严格的组织学方法。该目标的目标是开发估计眼睛中RGC含量的方法。为 这种疾病会导致不可逆的视力丧失,因此准确评估视功能也很重要。 原则上,OCT测量的RGC含量估计值之间也应该有很好的对应关系 and that from visual视觉threshold阈值.由于结构性措施是客观的,可变性较小, 使用结构测量准确预测视力。然而,两者之间存在显著差异。 结构和功能措施。这种分离的部分原因是视觉功能测试不 使用适当的空间采样和刺激大小。在这些实验中,我们将研究 使用更高的空间密度和不同的刺激大小(SA3)的RGC内容和视觉阈值之间。我们 目标是建立基于非侵入性结构成像的稳健方法来预测视觉功能。总的来说, 这些研究旨在提高我们对疾病病理生理学的理解, 在临床实践中进行监测。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nimesh Bhikhu Patel其他文献

Nimesh Bhikhu Patel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nimesh Bhikhu Patel', 18)}}的其他基金

OCTA and Glaucoma Progression in the Non-Human Primate
非人类灵长类动物的 OCTA 和青光眼进展
  • 批准号:
    10649710
  • 财政年份:
    2022
  • 资助金额:
    $ 38.25万
  • 项目类别:
OCTA and Glaucoma Progression in the Non-Human Primate
非人类灵长类动物的 OCTA 和青光眼进展
  • 批准号:
    10415689
  • 财政年份:
    2022
  • 资助金额:
    $ 38.25万
  • 项目类别:
Relating Structure to Function in Optic Neuropathies
视神经病变的结构与功能的关系
  • 批准号:
    10334429
  • 财政年份:
    2019
  • 资助金额:
    $ 38.25万
  • 项目类别:
Retinal Nerve Fiber Layer Area in Aging and Glaucoma
衰老和青光眼中的视网膜神经纤维层区域
  • 批准号:
    8165940
  • 财政年份:
    2011
  • 资助金额:
    $ 38.25万
  • 项目类别:
Retinal Nerve Fiber Layer Area in Aging and Glaucoma
衰老和青光眼中的视网膜神经纤维层区域
  • 批准号:
    8306705
  • 财政年份:
    2011
  • 资助金额:
    $ 38.25万
  • 项目类别:
Retinal Nerve Fiber Layer Area in Aging and Glaucoma
衰老和青光眼中的视网膜神经纤维层区域
  • 批准号:
    8531255
  • 财政年份:
    2011
  • 资助金额:
    $ 38.25万
  • 项目类别:
Retinal Nerve Fiber Layer Area in Aging and Glaucoma
衰老和青光眼中的视网膜神经纤维层区域
  • 批准号:
    8720774
  • 财政年份:
    2011
  • 资助金额:
    $ 38.25万
  • 项目类别:
Biological Imaging Module
生物成像模块
  • 批准号:
    10724942
  • 财政年份:
    1997
  • 资助金额:
    $ 38.25万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了